PI3K signalling
The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the r...
I tiakina i:
| Ngā kaituhi matua: | , , |
|---|---|
| Hōputu: | Online |
| Reo: | Ingarihi |
| I whakaputaina: |
Frontiers Media SA
2021
|
| Ngā marau: | |
| Urunga tuihono: | 17811 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
| _version_ | 1869524400775102464 |
|---|---|
| author | Martin Turner Klaus Okkenhaug Michael R. Gold |
| author_browse | Klaus Okkenhaug Martin Turner Michael R. Gold |
| author_facet | Martin Turner Klaus Okkenhaug Michael R. Gold |
| author_sort | Martin Turner |
| collection | Directory of Open Access Books |
| description | The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the role of this pathway in cells of the immune system has been made in recent years, starting with analysis of various PI3K and Pten knockout mice and subsequently mTOR and Foxo knockout mice. Together, these experiments have revealed how PI3Ks control B cell and T cell development, T helper cell differentiation, regulatory T cell development and function, B cell and T cell trafficking, immunoglobulin class switching and much, much more. The PI3Kd inhibitor idelalisib has recently been approved for the treatment of B cell lymphoma. Clinical trials of other PI3K inhibitors in autoimmune and inflammatory diseases are also in progress. This is an opportune time to consider a Research Topic considering when what we have learned about the PI3K signalling module in lymphocyte biology and how this is making an impact on clinical immunology and haematology. |
| format | Online |
| id | doab-20.500.12854ir-56255 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-562552024-03-31T13:11:03Z PI3K signalling Martin Turner Klaus Okkenhaug Michael R. Gold R5-920 RC581-607 B cell PI3K/AKT/mTOR Signal Transduction T cell PI3K pathway inhibitors thema EDItEUR::M Medicine and Nursing The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the role of this pathway in cells of the immune system has been made in recent years, starting with analysis of various PI3K and Pten knockout mice and subsequently mTOR and Foxo knockout mice. Together, these experiments have revealed how PI3Ks control B cell and T cell development, T helper cell differentiation, regulatory T cell development and function, B cell and T cell trafficking, immunoglobulin class switching and much, much more. The PI3Kd inhibitor idelalisib has recently been approved for the treatment of B cell lymphoma. Clinical trials of other PI3K inhibitors in autoimmune and inflammatory diseases are also in progress. This is an opportune time to consider a Research Topic considering when what we have learned about the PI3K signalling module in lymphocyte biology and how this is making an impact on clinical immunology and haematology. 2021-02-11T22:55:33Z 2021-02-11T22:55:33Z 2015-12-10 11:59:06 2015 book 17811 16648714 9782889194193 https://directory.doabooks.org/handle/20.500.12854/56255 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/PI3K_signalling/457 http://journal.frontiersin.org/researchtopic/568/pi3k-signalling Frontiers Media SA 10.3389/978-2-88919-419-3 10.3389/978-2-88919-419-3 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889194193 139 open access |
| spellingShingle | R5-920 RC581-607 B cell PI3K/AKT/mTOR Signal Transduction T cell PI3K pathway inhibitors thema EDItEUR::M Medicine and Nursing Martin Turner Klaus Okkenhaug Michael R. Gold PI3K signalling |
| title | PI3K signalling |
| title_full | PI3K signalling |
| title_fullStr | PI3K signalling |
| title_full_unstemmed | PI3K signalling |
| title_short | PI3K signalling |
| title_sort | pi3k signalling |
| topic | R5-920 RC581-607 B cell PI3K/AKT/mTOR Signal Transduction T cell PI3K pathway inhibitors thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RC581-607 B cell PI3K/AKT/mTOR Signal Transduction T cell PI3K pathway inhibitors thema EDItEUR::M Medicine and Nursing |
| url | 17811 |
| work_keys_str_mv | AT martinturner pi3ksignalling AT klausokkenhaug pi3ksignalling AT michaelrgold pi3ksignalling |